These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30626577)

  • 1. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2019 Jan; 364():k4810. PubMed ID: 30626577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2020 Oct; 371():m3873. PubMed ID: 33115755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2015 May; 350():h2135. PubMed ID: 26013557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    Vinogradova Y; Dening T; Hippisley-Cox J; Taylor L; Moore M; Coupland C
    BMJ; 2021 Sep; 374():n2182. PubMed ID: 34588168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.
    Panay N; Nappi RE; Stute P; Palacios S; Paszkowski T; Kagan R; Archer DF; Héroux J; Boolell M
    Maturitas; 2023 Jun; 172():23-31. PubMed ID: 37084589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
    Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
    Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
    Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P
    Menopause; 2011 Oct; 18(10):1052-9. PubMed ID: 21775912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
    Canonico M; Plu-Bureau G; Lowe GD; Scarabin PY
    BMJ; 2008 May; 336(7655):1227-31. PubMed ID: 18495631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
    Parkin L; Sharples K; Hernandez RK; Jick SS
    BMJ; 2011 Apr; 342():d2139. PubMed ID: 21511804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy and the risk of venous thromboembolism.
    Rachoń D; Teede H
    Climacteric; 2008 Aug; 11(4):273-9. PubMed ID: 18645692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
    Roach RE; Lijfering WM; Helmerhorst FM; Cannegieter SC; Rosendaal FR; van Hylckama Vlieg A
    J Thromb Haemost; 2013 Jan; 11(1):124-31. PubMed ID: 23136837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?
    Simon JA
    Menopause; 2014 Jul; 21(7):769-83. PubMed ID: 24398406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy and venous thromboembolism among postmenopausal women.
    Scarabin PY
    Front Horm Res; 2014; 43():21-32. PubMed ID: 24943295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
    Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P
    Menopause; 2018 Nov; 25(11):1297-1305. PubMed ID: 30358726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
    Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
    Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
    Canonico M
    Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
    Speroff L
    Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
    Renoux C; Dell'aniello S; Garbe E; Suissa S
    BMJ; 2010 Jun; 340():c2519. PubMed ID: 20525678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.